This year’s CEO outlook article in Life Science Leader’s annual outlook issue, published in December, has 15 CEOs taking part! Some members of this year’s CEO class were posed a question around what COVID-19 induced trends they envisioned sticking around well beyond the end of this pandemic.
Unprecedented. That’s the word used ad nauseam to describe much of what we experienced in 2020. And while many of these moves were unprecedented at the time, now that they’ve been done, they now serve as a precedent. This makes you wonder just how many COVID-19 causations will continue into 2021 and beyond?
Chief Editor Rob Wright talks about the last time he spoke with Henri Termeer, who was a mentor to Paula Ragan, Ph.D., cofounder and CEO of X4 Pharmaceuticals (subject of the November 2020 cover feature in Life Science Leader).
Paula Ragan, Ph.D., cofounder and CEO of X4 Pharmaceuticals (subject of the November 2020 cover feature in Life Science Leader), talks about how participating in team sports can help with leadership skills later in life.
David Lucchino, cofounder and CEO of Frequency Therapeutics, discusses how he came to meet company cofounders Robert Langer, Sc.D., and Chris Loose, Ph.D., along with transitioning from med tech to biopharma.
Life Science Leader editorial advisory board member Kenneth Moch, co-founder or CEO of six life science companies, discusses ethical considerations regarding the distribution and delivery of an approved COVID-19 vaccine within a given country.
Newest Life Science Leader editorial advisory board member, Pamela Reilly Contag, Ph.D., cofounder and CEO of BioEclipse, provides a comprehensive response to recent “Ask The Board” question, “What has been the greatest biopharma business related insight you have gained from continued operation during the first half of this year?”
Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, his latest biopharma entrepreneurial venture, provides insight into the music industry, as he happens to also be a professional musician.